Clesrovimab · Enflonsia
Monoclonal antibody
Also known as MK-1654
Evidence outlook
Approved: Respiratory Syncytial Virus Infection
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Phase 4 (1)
What this study did
Competitive landscape
This drug's own stage for Respiratory Syncytial Virus Infection: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Clesrovimab (Enflonsia): this drug | Approved | Monoclonal antibody | RSV F protein | not yet graded | No reviewed efficacy summary in this indication | |
| mRESVIA | Approved | Vaccine | RSV pre-F protein | Partial signal | NCT05330975: Part A (mRNA-1345 with Afluria Quadrivalent vs mRNA-1345 alone), RSV-A day 29: GMT ratio 0.807 (95% CI 0.668 to 0.974), lower bound above 0.667, non-inferior; seroresponse difference -11.2% (95% CI -17.9 to -4.1), lower bound below -10%, non-inferiority not shown. Part B (with SARS-CoV-2 vaccine): RSV-A GMT ratio 0.796 (95% CI 0.702 to 0.901) and seroresponse difference -4.4% (95% CI -9.9 to 1.0), both non-inferior (CT.gov posted analyses). | |
| EDP-323 | Phase 2 | Small molecule | RSV L protein | Partial signal | NCT06170242: Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC) (Day 1 to Day 12): EDP-323 High Dose 99.05 log10 copies/mL*hours (Standard Deviation 133.325) | EDP-323 Low Dose 82.28 log10 copies/mL*hours (Standard Deviation 158.033) | Placebo 657.45 log10 copies/mL*hours (Standard Deviation 396.743) | |
| Zelicapavir | Phase 2 | Small molecule | RSV N protein (nucleoprotein) | Weak signal | NCT05568706: Time to resolution of the four LRTD symptoms to mild (primary), zelicapavir 800 mg daily for 5 days vs placebo: median 5.0 vs 4.1 days (CT.gov), with no effect per the sponsor. Time to complete LRTD symptom resolution: 12.5 vs 13.0 days (mITT) and 12.0 vs 15.0 days (HR3), no test posted. missed NCT04633187: Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication (Day 1 through Day 28): EDP-938 0 Participants | Placebo 1 Participants | |
| GSK5893818 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0256 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0291 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0340 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0341 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Enflonsia (Clesrovimab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.